Citicoline vs Alpha-GPC: Not the Same Thing
Updated: 5 days ago
Citicoline and alpha-GPC are both sold as choline for the brain, and the comparison usually ends with somebody declaring a winner. The honest answer is narrower. They are different molecules, they have been tested in different people, and almost nobody has tested them head-to-head in healthy adults. Citicoline has the stronger record in people without a diagnosis. Alpha-GPC has more of its record in clinical populations — where a 2025 meta-analysis actually put it ahead of citicoline. Here is what each compound is, what the trials measured, and where the evidence runs out.
In this article: Both deliver choline. That is where the similarity ends. · What the trials actually measured · A European regulator looked at this and said no · The 2025 meta-analysis that favors alpha-GPC · The alpha-GPC safety question, fairly stated · So how do you actually choose? · Where Great Billiom Citicoline fits
Both deliver choline. That is where the similarity ends.
Choline is the raw material your body uses to build acetylcholine, and the case for supplementing starts there. The NIH Office of Dietary Supplements describes choline as "needed to produce acetylcholine, an important neurotransmitter for memory, mood, muscle control, and other brain and nervous system functions," and separately as "needed to synthesize phosphatidylcholine and sphingomyelin, two major phospholipids vital for cell membranes." The Adequate Intake is 550 mg a day for adult men and 425 mg for adult women, while average US intake sits at 402 mg and 278 mg respectively. Most adults are under the mark.
Where the two compounds diverge is what else rides along. Citicoline is cytidine 5'-diphosphocholine — CDP-choline. The Alzheimer's Drug Discovery Foundation's non-commercial review describes it as "a naturally occurring compound that serves as a precursor for essential cellular nutrients, including choline." It carries a cytidine group alongside the choline, which is the structural difference people point to.
Alpha-GPC — choline alphoscerate, or L-α glycerylphosphorylcholine — delivers choline on a glycerophosphate backbone instead. No cytidine. In several European and Asian markets it is not a supplement at all but a prescription product used in cognitive decline, which turns out to matter enormously when you read the research, because it shapes who ended up in the studies.
So "which is better" is already the wrong shape of question. The useful one is: better at what, and measured in whom? If you want the groundwork first, our overview of citicoline and cognitive health covers what the compound is before the comparison starts. Our own Citicoline CDP Choline is the CDP-choline form discussed throughout this article.
What the trials actually measured
Citicoline (CDP-choline) | Alpha-GPC (choline alphoscerate) | |
Also called | CDP-choline, cytidine 5'-diphosphocholine | Choline alphoscerate, L-α-GPC |
Delivers | Cytidine plus choline | Choline on a glycerophosphate backbone |
Healthy-adult RCT | 100 adults, 500 mg/day, 12 weeks (Nakazaki 2021) | We found no placebo-controlled trial of comparable size in healthy adults |
Head-to-head | 3 RCTs, 358 dementia patients: alpha-GPC favored on clinician-rated scales; no difference on memory or word fluency (Sagaro & Amenta 2025) | Same three trials |
EU regulatory view | EFSA 2024: memory claim not substantiated | No equivalent opinion reviewed here |
Large observational data | — | Stroke aHR 1.46 (Lee 2021); slower dementia conversion, HR 0.899 (Kim 2025) |
The one trial that gets cited constantly for citicoline is worth reading properly. Nakazaki and colleagues, publishing in The Journal of Nutrition in 2021, ran a randomized, double-blind, placebo-controlled trial: 100 healthy older adults with age-associated memory impairment, 500 mg of citicoline a day, 12 weeks. The citicoline group "showed significantly greater improvements in secondary outcomes of episodic memory (assessed by the Paired Associate test), compared with those on placebo (mean: 0.15 vs. 0.06, respectively, P = 0.0025)," and composite memory improved by 3.78 against 0.72 for placebo.
Note the phrase the authors themselves used: secondary outcomes. A trial's primary outcome is the one it was designed and powered to answer. Wins on secondary measures are real findings and weaker evidence than a primary-outcome result, and any honest summary says so.
A European regulator looked at this and said no
In July 2024, the EFSA Panel on Nutrition, Novel Foods and Food Allergens assessed a health claim for citicoline and memory. Their conclusion was blunt: "a cause-and-effect relationship has not been established between the consumption of citicoline (CDP-Choline) inner salt and improvement, maintenance or reduced loss of memory in middle-aged or elderly adults encountering age-associated subjective memory impairment."
The Panel's reasoning is the useful part. Weighing the evidence, they noted that "only one randomised controlled trial in healthy participants showed a beneficial effect of citicoline on episodic memory when consumed at doses of 500 mg/day for 12 weeks, whereas this effect has not been observed in another study using citicoline at doses of 1 g/day for 3 months." They added that no convincing mechanism had been demonstrated in humans beyond the body's own choline synthesis.
That is a regulator declining a memory claim for the ingredient in our own product, and we would rather you read it here than find it later. The Alzheimer's Drug Discovery Foundation lands in a similar place, concluding that "due to discrepancies across studies, there is insufficient evidence that it is beneficial in healthy people with otherwise good cognition."
Anyone comparing the two compounds should hold alpha-GPC to exactly this standard. The interesting fact is that the head-to-head literature is almost entirely in patients, not in healthy people — which makes the strongest published comparison an awkward one for citicoline.
The 2025 meta-analysis that favors alpha-GPC
Sagaro and Amenta published a systematic review and meta-analysis in Frontiers in Neurology in 2025 pooling three randomized trials — 358 participants, all with dementia disorders. On clinician-rated SCAG scales, alpha-GPC came out ahead of citicoline on cognitive dysfunction, interpersonal relationships, affective disorders and apathy. Their conclusion: "choline alphoscerate is more effective than citicoline in improving the clinical conditions of dementia patients."
Three things keep that from settling the argument. The authors flag limited sample sizes and open-label designs and call for larger trials. On the two most recognizable cognitive measures, "there was no significant difference between the choline alphoscerate and citicoline treatment groups on memory or word fluency tests." And the population was people with diagnosed dementia under medical care — which tells you very little about a healthy adult buying a supplement. It is still the strongest direct comparison anyone has published, and it does not favor citicoline.
The alpha-GPC safety question, fairly stated
Two enormous Korean database studies exist, and they point in opposite directions.
In JAMA Network Open in 2021, Lee and colleagues followed 12,008,977 people for ten years. Compared with non-users, alpha-GPC users "had a higher risk for total stroke (aHR, 1.46; 95% CI, 1.43-1.48)," with a dose-response pattern across duration of use. Then in 2025, Kim and colleagues followed 508,107 people newly diagnosed with mild cognitive impairment and reported that alpha-GPC users "had a lower risk of progression to Alzheimer's disease dementia (hazard ratio = 0.899, 95 % confidence interval: 0.882–0.918)."
Both are observational, and the first study's authors name the catch themselves: "α-GPC users were older and had more comorbidities than α-GPC nonusers, which suggests that α-GPC users may already have subclinical atherosclerotic changes." In a country where alpha-GPC is prescribed to people with cognitive symptoms, the people taking it were sicker to begin with. That is confounding by indication, and it can manufacture an association out of nothing.
The responsible reading is not "alpha-GPC is dangerous." It is that a prescription-adjacent compound carries a research literature shaped by who gets prescribed it, and that no one should settle this question from a blog post — including ours.
So how do you actually choose?
Strip out the marketing and the decision comes down to a few honest observations. The direct evidence in healthy adults is thin for both compounds, and it is less thin for citicoline: one properly randomized, placebo-controlled trial at 500 mg a day, with wins on secondary outcomes. The only published head-to-head evidence sits in dementia patients and modestly favors alpha-GPC on clinician-rated scales, with no difference on memory testing. And alpha-GPC's observational record is genuinely mixed in a way citicoline's is not.
On dosing, the Alzheimer's Drug Discovery Foundation notes typical citicoline doses of "250–1,000 mg/day," observes that lower doses "may provide more benefit than higher doses" in healthy people, and reports that "no serious safety issues have been reported with citicoline treatment." For choline overall, the NIH sets a Tolerable Upper Intake Level of 3,500 mg a day for adults.
If you are on any medication, or managing a diagnosed condition, this is a conversation for your doctor rather than a purchase decision. That applies to both compounds.
Where Great Billiom Citicoline fits
Everything above about dementia trials and stroke cohorts describes people with diagnosed conditions under medical care. None of it is a statement about what a dietary supplement does for a healthy adult, and none of it is a claim about ours.
What we can tell you is what is in the bottle. Great Billiom Citicoline CDP Choline is the CDP-choline form — the compound EFSA characterized and the one Nakazaki's trial used. Each capsule is 500 mg; the label serving is two capsules, 1,000 mg. A bottle holds 90 capsules, which is a 45-day supply at the label serving, and costs $19.99, or $17.99 on Subscribe & Save — $0.44 per serving. It supports memory, focus and mental clarity, and it does that without caffeine or sugar.
We are not going to tell you it is the deciding factor in your workday. The research above is exactly as far as the research goes.
Key takeaways
Citicoline is CDP-choline (cytidine plus choline); alpha-GPC is choline on a glycerophosphate backbone. Different molecules, not interchangeable versions of one thing.
Citicoline has the stronger healthy-adult evidence: one randomized, placebo-controlled trial, 100 adults, 500 mg a day for 12 weeks — with wins on secondary outcomes, not the primary one.
EFSA reviewed that evidence in 2024 and concluded a cause-and-effect relationship with memory has not been established. We would rather say so than leave you to find it.
The only published head-to-head comparison is a 2025 meta-analysis in 358 dementia patients, and it favored alpha-GPC on clinician-rated scales — while finding no difference on memory or word fluency.
Alpha-GPC's two large Korean cohort studies disagree with each other, and the stroke finding is heavily confounded by who gets prescribed it.
If citicoline is the form you want, ours is 500 mg per capsule and 1,000 mg per two-capsule serving, 90 capsules for $19.99. If this article has left you undecided, that is a fair place to land — the evidence is genuinely unfinished, and you are welcome to come back to it. Our guide to supplements for memory and focus walks through the citicoline trials in healthy adults if you are still comparing.
Frequently asked questions
Is CDP-choline the same as citicoline?
Yes. Citicoline and CDP-choline are two names for the same compound, cytidine 5'-diphosphocholine. EFSA's 2024 opinion refers to it as "citicoline (cytidine 5-diphosphocholine, CDP-Choline) inner salt." If a label says CDP-choline and another says citicoline, you are looking at the same ingredient under different naming conventions.
Which is stronger, citicoline or alpha-GPC?
Neither has been shown stronger in healthy adults, because no adequately sized head-to-head trial in that group has been published. The one published comparison — a 2025 meta-analysis of three trials in 358 dementia patients — favored alpha-GPC on clinician-rated scales but found no difference on memory or word fluency tests.
Can you take citicoline and alpha-GPC together?
There is no trial evidence on the combination, so there is no informed answer available. Both are choline sources, and the NIH sets a Tolerable Upper Intake Level for choline of 3,500 mg a day for adults. Anyone stacking choline sources, or taking medication, should raise it with a doctor first.
How much citicoline do the studies use?
The Alzheimer's Drug Discovery Foundation reports typical doses of 250–1,000 mg a day, and notes that in healthy people lower doses may offer more benefit than higher ones. The 2021 trial in healthy older adults used 500 mg a day for 12 weeks. Trials in patients with neurological disease generally used 1,000 mg a day.
Does alpha-GPC really increase stroke risk?
A 2021 JAMA Network Open study of 12 million people found a higher adjusted risk among users, but its authors noted those users "were older and had more comorbidities" — meaning they may have been at higher risk before taking anything. A 2025 study in the same population found slower dementia progression. Observational data cannot settle this.
Megan Elliott, Content Editor at Great Billiom. Every claim in this article is sourced from the primary research linked above. Read our editorial standards → thegreatbilliom.com/editorial-standards
Sources
EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA). "'Citicoline' and support of the memory function: Evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006." EFSA Journal, 2024;22(7):e8861.
Nakazaki E, Mah E, Sanoshy K, Citrolo D, Watanabe F. "Citicoline and Memory Function in Healthy Older Adults: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial." The Journal of Nutrition, 2021;151(8):2153–2160.
Sagaro GG, Amenta F. "Comparison of the effects of choline alphoscerate and citicoline in patients with dementia disorders: a systematic review and meta-analysis." Frontiers in Neurology, 2025.
Lee G, Choi S, Chang J, et al. "Association of L-α Glycerylphosphorylcholine With Subsequent Stroke Risk After 10 Years." JAMA Network Open, 2021.
Kim HK, Park S, Kim SW, et al. "Association between L-α glycerylphosphorylcholine use and delayed dementia conversion: A nationwide longitudinal study in South Korea." The Journal of Prevention of Alzheimer's Disease, 2025.
Alzheimer's Drug Discovery Foundation. "Cognitive Vitality: Citicoline."
NIH Office of Dietary Supplements. "Choline: Fact Sheet for Health Professionals."
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Individual results may vary.
Comments